U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07624201) titled 'Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer' on May 21.
Brief Summary: This study aims to evaluate the efficacy and safety of neoadjuvant trastuzumab rezetecan combined with adebrelimab for the treatment of HER2-positive muscle-invasive bladder cancer.
Study Start Date: June 01
Study Type: INTERVENTIONAL
Condition:
Muscle-Invasive Bladder Cancer (MIBC)
Intervention:
DRUG: Trastuzumab Rezetecan Combined with Adebelizumab
Trastuzumab Rezetecan 3.2 mg/kg, Q3W, in combination with Adebrelimab 1200 mg, Q3W, for a total of 3 cycles. Subjects will undergo preoperative ...